|Bid||10,100.00 x 0|
|Ask||11,348.00 x 0|
|Day's range||11,074.00 - 11,230.00|
|52-week range||8,090.32 - 11,540.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||104.47|
|Earnings date||10 Nov 2022|
|Forward dividend & yield||2.22 (2.00%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||117.25|
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
The healthcare industry can make for a safe place to invest regardless of the macroeconomic conditions. A couple of healthcare stocks that are diversified and that could be good buys heading into the new year are AstraZeneca (NASDAQ: AZN) and PetMed Express (NASDAQ: PETS). AstraZeneca's business performed well in 2022, but its stock isn't doing as well as perhaps it should be.
Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20. The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.